Multiple Sclerosis and Natalizumab

  title={Multiple Sclerosis and Natalizumab},
  author={Domenico Fiore},
  journal={American Journal of Therapeutics},
  • D. Fiore
  • Published 1 November 2007
  • Medicine
  • American Journal of Therapeutics
Natalizumab (NTZ), defined as “the first of a new class of drugs known as elective adhesion molecule inhibitors” was developed at the beginning of 2003 to treat relapsing-remitting multiple sclerosis (MS) and was approved in the United States in November 2004. In February 2005, the production of NTZ was suspended by Producer Firms on account of the occurrence of two serious adverse events: two patients who had been taking NTZ manifested a progressive multifocal leukoencephalopathy; the patients… 
Advances in Understanding the Pathogenesis of Inflammatory Bowel Disease
This chapter reviews the current knowledge of the pathogenesis of IBD and presents new therapies, and sheds light on the novel agents under development for treatment of these potentially disabling systemic disorders.
Monoclonal Antibodies as Therapeutic Agents
Immunoconjugates which are comprised of monoclonal antibody linked to a chemotherapeutic agent or source(s) of radiation are discussed to treat cancer.
Novel Anti-Inflammatory Action of Edelfosine Lacking Toxicity with Protective Effect in Experimental Colitis
The data identify edelfosine as a novel anti-inflammatory drug by abating neutrophil infiltration through L-selectin shedding and may provide a new therapeutic approach for inflammatory bowel disease free from toxicity.
Quantitative uncertainty analysis of gravity disturbance. The case of the Geneva Basin (Switzerland)
Abstract Gravity data from the International Gravimetric Bureau and the Gravimetric Atlas of Switzerland have been used to evaluate their application and limitations as a subsurface investigation


A controlled trial of natalizumab for relapsing multiple sclerosis.
In a placebo-controlled trial, treatment with natalizumab led to fewer inflammatory brain lesions and fewer relapses over a six-month period in patients with relapsing multiple sclerosis.
Diagnosis and Treatment of Multiple Sclerosis and Amyotrophic Lateral Sclerosis: Neuropathies From Bordetella Pertussis
  • D. Fiore
  • Medicine
    American journal of therapeutics
  • 2003
The pathogenesis of the neuropathies from Bordetella pertussis is reassessed and an extended antibiotic therapy to clear mucosae and to prevent reinfections is necessary.
Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis
It is suggested that sICAM-1 index can be a better marker of intrathecal sICam-1 synthesis than CSF levels and provide additional insights, in vivo, into the blood-brain barrier mechanisms underlying MRI Gd-enhancement in clinically active RR MS.
Summary Because bottled water is beginning to assume a prominent place in the diet of adults and children, its health effects require evaluation. In this paper, we analyze the content of the three
Manuale di Immunologia
  • Padova: Piccin Ed.; 1981:22,
  • 2007
Sclerosi multipla (parte prima)
  • Medico E Bambino Pagine Electroniche
  • 2006
Malattie da B. Pertussis nell'Uomo -EOS
  • 2001
Pertussis nell’Uomo – EOS
  • 2001
Immunopatogenesi della sclerosi multipla: ruolo della barriera emato-encefalica
  • From the Volume Abstract del Congresso SNO,
  • 2000
Immunopatogenesi della sclerosi multipla: ruolo della barriera emato-encefalica. From the Volume Abstract del Congresso SNO
  • 2000